Recent advancements in immunotherapy, which boosts antitumor activity using cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) inhibitors, have altered the therapeutic approach for a variety of cancers (Naidoo et al., 2020). The gene discussed is PDCD1; the disease is cancer.